middle.news
Neurizon Secures US Patent for NUZ-001, Bolstering ALS Treatment Prospects
5:34pm on Sunday 1st of June, 2025 AEST
•
Biotechnology
Read Story
Neurizon Secures US Patent for NUZ-001, Bolstering ALS Treatment Prospects
5:34pm on Sunday 1st of June, 2025 AEST
Key Points
USPTO grants method-of-use patent for NUZ-001 covering neurodegenerative diseases and cancer
Patent protection extends in the US market until 2039
Follows FDA Orphan Drug Designation for NUZ-001 in May 2024
Strengthens Neurizon’s commercial potential and licensing leverage
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NUZ
OPEN ARTICLE